# Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct07641036/  
OnCo record `nct07641036` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine, Cyclophosphamide in gallbladder cancer, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT07641036 by Beijing Biotech, with 30 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide. Conditions listed: Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07641036
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Biomarker-Selected Study of Allogeneic Dual-Target HER2/CEACAM5 Chimeric Antigen Receptor Natural Killer Cells (EB-HC01) in Participants With Unresectable or Metastatic Cholangiocarcinoma and Other Biliary Tract Cancers
- Sponsor: Beijing Biotech
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07641036: https://clinicaltrials.gov/study/NCT07641036

## Connected records

- cancers: [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07641036.json